{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:28:39Z","timestamp":1784820519860,"version":"3.55.0"},"reference-count":60,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Advanced glycation end products (AGEs) are biologically active compounds formed physiologically throughout a sequence of chemical reactions, to generate highly oxidant-reactive aldehydes that combine covalently to proteins. They accumulate slowly in tissues during ageing but also in metabolic and selected inflammatory disorders. Accumulation of AGEs occurs more rapidly and intensely in the skin and serum of patients with type 2 diabetes, obesity, cardiovascular diseases, chronic renal insufficiency, and non-alcoholic fatty liver disease and also in the skin of patients with psoriasis. All of the above conditions are intimately associated with psoriasis. Interaction of AGEs with their receptors (RAGEs) stimulates cellular signaling with the formation of reactive oxygen species and activation of nuclear factor kappa light chain enhancer of activated B (NF-kB), which is a key regulator in the expression of inflammatory mediators and the production of oxidative stress. Thus, AGEs may play an interesting pathogenic role in the intersection of inflammatory and metabolic diseases, may represent a biomarker of inflammation and a potential target for novel therapeutic strategies. This is a narrative review with the objective to summarize current evidence on the role of AGEs in psoriasis.<\/jats:p>","DOI":"10.3390\/vaccines11030617","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T02:33:16Z","timestamp":1678329196000},"page":"617","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Advanced Glycation End Products and Psoriasis"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7492-8010","authenticated-orcid":false,"given":"Martina","family":"Maurelli","sequence":"first","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-9001","authenticated-orcid":false,"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8548-0493","authenticated-orcid":false,"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"ref_1","first-page":"e629","article-title":"Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment","volume":"36","author":"Marella","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.2340\/00015555-2661","article-title":"Advanced Glycation End Products are increased in the skin and blood of patients with severe psoriasis","volume":"97","author":"Papagrigoraki","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Papagrigoraki, A., Maurelli, M., Del Giglio, M., Gisondi, P., and Girolomoni, G. (2017). Advanced Glycation End Products in the pathogenesis of psoriasis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112471"},{"key":"ref_4","first-page":"1","article-title":"Tailored biological treatment for patients with moderate to severe psoriasis","volume":"9","author":"Maurelli","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_5","first-page":"1","article-title":"Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis","volume":"26","author":"Gisondi","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gisondi, P., Geat, D., Maurelli, M., Degli Esposti, L., Bellinato, F., and Girolomoni, G. (2022). Cost per responder analysis of Secukinumab versus Adalimumab in the treatment of psoriatic disease. Vaccines, 10.","DOI":"10.3390\/vaccines10050646"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14712598.2021.1862082","article-title":"HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis","volume":"21","author":"Morelli","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.2147\/DMSO.S273147","article-title":"Diabetes and psoriasis: Different sides of the same prism","volume":"13","author":"Abramczyk","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fphar.2020.00117","article-title":"Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities","volume":"11","author":"Gisondi","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"880201","DOI":"10.3389\/fimmu.2022.880201","article-title":"Epidemiology of psoriasis and comorbid diseases: A narrative review","volume":"13","author":"Bu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10654-018-0366-z","article-title":"Body mass index, abdominal fatness, weight gain and the risk of psoriasis: A systematic review and dose-response meta-analysis of prospective studies","volume":"33","author":"Aune","year":"2018","journal-title":"Eur. J. Epidemiol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Correa, T.L., Quitete, M.A.C., de Azevedo, L.T., Fraga, I.A.C., and Teixeira, L.C. (2022). Infarctus du myocarde, accident vasculaire c\u00e9r\u00e9bral et psoriasis: Une revue syst\u00e9matique des \u00e9tudes observationnelles [Myocardial infarction, stroke, and psoriasis: A systematic review of observational studies]. Ann. Cardiol. Angeiol., 16.","DOI":"10.1016\/j.ancard.2022.11.009"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.dsx.2019.01.009","article-title":"The association between psoriasis and diabetes mellitus: A systematic review and meta-analysis","volume":"13","author":"Mamizadeh","year":"2019","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/bjd.12101","article-title":"The association between psoriasis and dyslipidaemia: A systematic review","volume":"168","author":"Ma","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/jid.2011.365","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom","volume":"132","author":"Langan","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40618-022-01755-0","article-title":"Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: An updated systematic review and meta-analysis of observational studies","volume":"45","author":"Bellinato","year":"2022","journal-title":"J. Endocrinol. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/ard-2022-222787","article-title":"Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis","volume":"82","author":"Gessl","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"rkaa032","DOI":"10.1093\/rap\/rkaa032","article-title":"Systematic literature review of non-topical treatments for early, untreated (systemic therapy na\u00efve) psoriatic disease: A GRAPPA initiative","volume":"4","author":"Coates","year":"2020","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/PTT.S323300","article-title":"Reducing the risk of developing psoriatic arthritis in patients with psoriasis","volume":"12","author":"Gisondi","year":"2022","journal-title":"Psoriasis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/ecco-jcc\/jjz152","article-title":"Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease-a systematic review and meta-analysis","volume":"14","author":"Alinaghi","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s001250051591","article-title":"Advanced glycation endproducts: A review","volume":"44","author":"Singh","year":"2001","journal-title":"Diabetologia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00726-003-0017-9","article-title":"Maillard reaction products in tissue proteins: New products and new perspectives","volume":"25","author":"Thorpe","year":"2003","journal-title":"Amino Acids"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Shen, C.Y., Lu, C.H., Wu, C.H., Li, K.J., Kuo, Y.M., Hsieh, S.C., and Yu, C.L. (2020). The development of Maillard reaction, and Advanced Glycation End Product (AGE)-Receptor for AGE (RAGE) signaling inhibitors as novel therapeutic strategies for patients with AGE-related diseases. Molecules, 25.","DOI":"10.3390\/molecules25235591"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11654","DOI":"10.1016\/S0021-9258(18)99007-1","article-title":"Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo","volume":"266","author":"Dyer","year":"1991","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fphys.2013.00242","article-title":"Interaction of aldehydes derived from lipid peroxidation and membrane proteins","volume":"4","author":"Pizzimenti","year":"2013","journal-title":"Front. Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00403-013-1362-5","article-title":"Serum methylglyoxal level and its association with oxidative stress and disease severity in patients with psoriasis","volume":"305","author":"Kaur","year":"2013","journal-title":"Arch. Dermatol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/10715762.2013.815348","article-title":"Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): An overview of their mechanisms of formation","volume":"47","author":"Vistoli","year":"2013","journal-title":"Free Radic. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1468-3083.2011.04024.x","article-title":"Advanced protein glycation in psoriasis","volume":"26","author":"Wielkoszynski","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1479-5876-7-17","article-title":"RAGE (receptor for advanced glycation end products), RAGE ligands, and their role in cancer and inflammation","volume":"7","author":"Sparvero","year":"2009","journal-title":"J. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3818196","DOI":"10.1155\/2020\/3818196","article-title":"Advanced Glycation End Products (AGEs): Biochemistry, signaling, analytical methods, and epigenetic effects","volume":"2020","author":"Perrone","year":"2020","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/MCO.0000000000000774","article-title":"Methods to assess advanced glycation end-products","volume":"24","author":"Jaisson","year":"2021","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/postgradmedj-2016-134579","article-title":"Skin autofluorescence, a non-invasive marker of advanced glycation end products: Clinical relevance and limitations","volume":"93","author":"Webb","year":"2017","journal-title":"Postgrad. Med. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1089\/dia.2009.0113","article-title":"Reference values of skin autofluorescence","volume":"12","author":"Koetsier","year":"2010","journal-title":"Diabetes Technol. Ther."},{"key":"ref_35","first-page":"38","article-title":"The serum level of oxidative stress and antioxidant markers in patients with psoriasis: A cross-sectional study","volume":"14","author":"Shakoei","year":"2021","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1111\/bjd.18807","article-title":"Psoriasin (S100A7) is increased in the serum of patients with moderate-to-severe psoriasis","volume":"182","author":"Maurelli","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ced.13370","article-title":"Serum levels of psoriasin (S100A7) and koebnerisin (S100A15) as potential markers of atherosclerosis in patients with psoriasis","volume":"43","author":"Awad","year":"2018","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jdermsci.2015.05.007","article-title":"Leucocyte derived koebnerisin (S100A15) and psoriasin (S100A7) are systemic mediators of inflammation in psoriasis","volume":"79","author":"Hattinger","year":"2015","journal-title":"J. Dermatol. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/ijd.15851","article-title":"Skin advanced glycation end products as a diagnostic and monitoring tool among psoriatic patients: How the therapy helps reduce cardiovascular disease risk","volume":"61","author":"Lanna","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Damasiewicz-Bodzek, A., and Nowak, A. (2022). Concentrations of N6-carboxymethyllysine (CML), N6-carboxyethyllysine (CEL), and soluble receptor for Advanced Glycation End-Products (sRAGE) are increased in psoriatic patients. Biomolecules, 12.","DOI":"10.3390\/biom12121870"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"112","DOI":"10.59566\/IJBS.2013.9112","article-title":"Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis","volume":"9","author":"Mezentsev","year":"2013","journal-title":"Int. J. Biomed. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.jid.5700070","article-title":"The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha","volume":"126","author":"Lohwasser","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1134\/S0026893313050191","article-title":"Role of receptor for advanced glycation end-products in pathogenesis of psoriasis","volume":"47","author":"Soboleva","year":"2013","journal-title":"Mol. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"829709","DOI":"10.3389\/fcvm.2022.829709","article-title":"Psoriasis increased the risk of adverse cardiovascular outcomes: A new systematic review and meta-analysis of cohort study","volume":"9","author":"Liu","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.bbadis.2019.01.006","article-title":"Impact of advanced glycation end products (AGEs) signaling in coronary artery disease","volume":"1865","author":"Kosmopoulos","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s10020-018-0060-3","article-title":"The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: A review","volume":"24","author":"Fishman","year":"2018","journal-title":"Mol. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/ijd.IJD_396_18","article-title":"Advanced Glycation End Products, a potential link between psoriasis and cardiovascular disease: A case-control study","volume":"64","author":"Ergun","year":"2019","journal-title":"Indian J. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2340\/00015555-2933","article-title":"Soluble receptor for Advanced Glycation End Products: A novel biomarker for psoriasis severity with therapeutic implications?","volume":"98","author":"Baran","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_49","first-page":"4016939","article-title":"Skin autofluorescence, as a measure of AGE accumulation in individuals suffering from chronic plaque psoriasis","volume":"2018","author":"Makulska","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s12325-020-01346-6","article-title":"Psoriasis and cardiovascular risk: A comprehensive review","volume":"37","author":"Masson","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/jdv.16273","article-title":"The role of the interleukin-23\/Th17 pathway in cardiometabolic comorbidity associated with psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/14656566.2019.1583207","article-title":"The pharmacological management of patients with comorbid psoriasis and obesity","volume":"20","author":"Chiricozzi","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PTT.S159163","article-title":"Type 2 diabetes and psoriasis: Links and risks","volume":"9","author":"Holm","year":"2019","journal-title":"Psoriasis"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clindermatol.2017.09.005","article-title":"Psoriasis and the metabolic syndrome","volume":"36","author":"Gisondi","year":"2018","journal-title":"Clin. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad Dermatol."},{"key":"ref_56","first-page":"438","article-title":"Chronic kidney disease in psoriasis: A cohort study","volume":"18","author":"Conti","year":"2020","journal-title":"J. Dtsch Dermatol. Ges"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"321","DOI":"10.25259\/IJDVL_372_19","article-title":"Prevalence and stages of chronic kidney disease in psoriasis and psoriatic arthritis: A cross-sectional study","volume":"87","author":"Mateo","year":"2021","journal-title":"Indian J. Dermatol. Venereol. Leprol"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/advances\/nmaa150","article-title":"The impact of low Advanced Glycation End Products diet on metabolic risk factors: A systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Sohouli","year":"2021","journal-title":"Adv. Nutr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/ATVBAHA.117.307263","article-title":"22016 ATVB plenary lecture: Receptor for advanced glycation endproducts and implications for the pathogenesis and treatment of cardiometabolic disorders: Spotlight on the macrophage","volume":"37","author":"Schmidt","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"13264","DOI":"10.1038\/s41598-021-92630-0","article-title":"Advanced glycation end products and their receptors in serum of patients with type 2 diabetes","volume":"11","author":"Indyk","year":"2021","journal-title":"Sci. Rep."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/3\/617\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:51:16Z","timestamp":1760122276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/3\/617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["vaccines11030617"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11030617","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]}}}